Orforglipron (Foundayo): A Guide for Practitioners
Prof Steve Davies Consultant Endocrinologist and Medical Director The MHRA has authorised Eli Lilly’s orforglipron (Foundayo), making the UK the first European country to approve this once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes.[1] Orforglipron is a non-peptide, GLP-1 receptor agonist through its binding mechanism is distinct from endogenous GLP-1. Its […]
